Can Immunotherapy Help Preserve Pancreatic Function in Children with Type 1 Diabetes?

Insulin therapy saves lives and controls blood sugar, but it doesn't stop the underlying problem: the immune system attacking the pancreas. By the time a child is diagnosed with Type 1 diabetes, about 80–90% of the insulin-producing beta cells have already been destroyed. The remaining cells are still under attack.

This is where immunotherapy enters the picture. Rather than simply replacing insulin, these treatments aim to quiet the autoimmune process and preserve whatever beta cell function remains. Even a small amount of natural insulin production can make a real difference in how easy diabetes is to manage and may help reduce long-term complications.

A systematic review and meta-analysis examined 12 clinical trials testing various immunotherapies, including Teplizumab, Imatinib, Etanercept, and others. Researchers pooled data on blood sugar control (HbA1c), natural insulin production (C-peptide), and daily insulin requirements.

The results were mixed but encouraging. Immunotherapy was associated with a statistically significant reduction in HbA1c levels—meaning better blood sugar control. Daily insulin needs also trended downward, though this difference wasn't quite statistically significant. Changes in C-peptide levels (a marker of natural insulin production) were not statistically significant.

These findings suggest that immunotherapy can help improve glycaemic control in children with newly diagnosed Type 1 diabetes, though the size of the benefit varies across studies.

This research represents an important shift in how scientists think about Type 1 diabetes treatment. Rather than accepting that the disease always means lifelong insulin dependence with no hope of preserving natural insulin production, researchers are testing whether intervening early in the disease process can change that trajectory.

However, it's important to be clear: these are investigational treatments in clinical trials. Immunotherapy is not yet standard care for children newly diagnosed with Type 1 diabetes. The TrialNet Study Group continues to launch new trials testing different immune interventions, building on evidence that every bit of preserved beta cell function matters.

If you're interested in participating in research or learning more about clinical trials testing new approaches to Type 1 diabetes, talk with your diabetes care team about what may be available in your region.

Origin: European Medical Journal (News report). Evidence: News report, corroborated with 1 indexed study. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.